IL-17和IL-23拮抗剂治疗银屑病研究进展

IL-17 and IL-23 targeting therapies in psoriasis

目前美国食品药品监督局(FDA)批准用于临床的IL-17抗体拮抗剂包括secukinumab、ixekizumab和brodalumab,三者治疗中度至重度斑块状银屑病皮损清除均优于对照组TNF-α拮抗剂,且安全性及耐受性均较好。三种IL-23拮抗剂risankizumab,guselkumab和tildrakizumab目前均在Ⅲ期临床试验中,初步临床试验结果表明三种药物治疗银屑病较对照组TNF-α拮抗剂具有更快达到皮疹改善、更高皮疹清除率和注射次数更少的优势。本文就上述六种生物制剂治疗银屑病的研究进展进行了综述。

IL-17 inhibitors of secukinumab,ixekizumab and brodalumab,approved by FDA in the treatment of psoriasis,have clinically been demonstrated to be more effective,tolerable and safe,compared to TNF-αinhibitors. Three IL-23 inhibitors including risankizumab,guselkumab and tildrakizumab are currently under phase III clinical trials. The primary results of the clinical trials showed the advantage of faster skin improvement,higher skin clearance and fewer injections than TNF-αinhibitors. The update of these six new biological agents in the treatment of psoriasis is reviewed in this article.